BRTX Share Price Performance

US$2.67

-28.13 (-91.33%)

US$160.00

Fair Value

US$2.67

-28.13 (-91.33%)

98.3% undervalued

US$160.00

Fair Value

US$2.67

US$160.00

US$1.00

US$15.00

Tue, 8 Sep 26

Fair ValueUS$160.00

Share Pricen/a

BRTX Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value US$160 98.3% undervalued

Regenerative Therapies And Obesity Trends Will Drive Long Term Earnings Upside

AnalystLowTarget's

Fair Value

Fair Value US$1 167.0% overvalued

Obesity Market And Spine Therapy Risks May Gradually Give Way To Long-Term Potential

AnalystHighTarget's

Fair Value

Fair Value US$15 82.2% undervalued

Regenerative Cell Therapies And BioCosmeceuticals Will Reshape Long Term Value Potential

About BRTX

Founded: n/a
Employees: 14
CEO: Mika Grasso
WebsiteView website: www.biorestorative.com

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Recent BRTX News & Updates

Announcement • Sep 05

BioRestorative Therapies, Inc. Announces CEO Changes, Effective August 26, 2026

On August 26, 2026, Katharyn Field advised the Board that she wished to step aside as the BioRestorative Therapies, Inc.'s Interim Chief Executive Officer and Chief Financial Officer, and the Board accepted her request effective as of that date. Ms. Field’s transition and resignation were not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. On August 26, 2026, the Board appointed Mika Grasso as the Company’s Interim Chief Executive Officer, effective immediately. Mr. Grasso recused himself from the Board’s deliberations and vote on his appointment. In connection with his appointment, Mr. Grasso ceased to serve as Chair and a member of the Audit Committee and as a member of the Compensation Committee and the Nominating and Corporate Governance Committee of the Board, and the Board appointed Steven Brown as Chair of the Audit Committee. On September 1, 2026, the Board also appointed Mr. Brown as Chairman of the Board. The Board has reconstituted its standing committees as follows: Audit Committee: Steven Brown (Chair), Jatinder Dhaliwal and Esha Randhawa; Compensation Committee: Jatinder Dhaliwal (Chair), Steven Brown and Esha Randhawa; and Nominating and Corporate Governance Committee: Esha Randhawa (Chair), Jatinder Dhaliwal and Steven Brown. The Board has designated Steven Brown as the Company’s “audit committee financial expert” within the meaning of Item 407(d)(5) of Regulation S-K. Mr. Grasso, age 29, has served as a director of the Company since June 2026 and served as Chair of the Audit Committee from July 2026 until August 2026. Mr. Grasso has served as a director of XORTX Therapeutics Inc. (Nasdaq: XRTX), a clinical-stage biopharmaceutical company, since March 2026 and as its Co-Chief Executive Officer since June 2026. Since March 2025, Mr. Grasso has served as Principal at Currensea Capital LLC, a management consulting firm through which he provides executive leadership, along with corporate strategy and capital markets advisory services to public and private companies. Mr. Grasso previously served as an Associate at Zions Capital Markets from November 2023 until March 2025, as an Investment Banking Associate at Paulson Investment Company from February 2022 until November 2023, as an Analyst at Goldman Sachs from August 2021 until February 2022 and as an Analyst on the Real Assets team at Power Systems Management from May 2020 until August 2021. Mr. Grasso previously served as a director of Nuwellis, Inc. (Nasdaq: NUWE) from January 2026 until March 2026. Mr. Grasso received his M.S. in Finance, with a concentration in Investment Management, and his B.S. in Business Administration from the University of Colorado Boulder, Leeds School of Business. Mr. Grasso was originally appointed to the Board in June 2026 as a designee of Bowery Group LLC (the “Lender”) pursuant to the Revolving Loan Agreement, dated June 10, 2026, between the Company and the Lender, as amended. Other than the foregoing, there is no arrangement or understanding between Mr. Grasso and any other person pursuant to which he was appointed as Interim Chief Executive Officer.

Recent updates

No updates

BioRestorative Therapies, Inc. Stock Price

BRTX Share Price Performance

BRTX Community Narratives

Regenerative Therapies And Obesity Trends Will Drive Long Term Earnings Upside

Obesity Market And Spine Therapy Risks May Gradually Give Way To Long-Term Potential

Regenerative Cell Therapies And BioCosmeceuticals Will Reshape Long Term Value Potential

Regenerative Therapies And Obesity Trends Will Drive Long Term Earnings Upside

Obesity Market And Spine Therapy Risks May Gradually Give Way To Long-Term Potential

Regenerative Cell Therapies And BioCosmeceuticals Will Reshape Long Term Value Potential

Trending Discussion

Recently Updated Narratives

BRTX: Governance Reset And Regulatory Cleanup Will Drive Future Upside

BRTX: Expanded Share Authorization Will Support Future Regenerative Platform Upside

BRTX: Phase 2 Progress And Share Expansion Will Drive Future Upside

Snowflake Analysis

BioRestorative Therapies, Inc. Key Details

About BRTX

Recent BRTX News & Updates

BRTX: Governance Reset And Regulatory Cleanup Will Drive Future Upside

BioRestorative Therapies, Inc. Announces CEO Changes, Effective August 26, 2026

Recent updates

BioRestorative Therapies, Inc. Competitors

OSR Health

Reviva Pharmaceuticals Holdings

Hepion Pharmaceuticals

AIM ImmunoTech